

A New Xanthone from the Bark Extract of Rheedia acuminata and Antiplasmodial Activity of Its Major Compounds

Guillaume Marti, Véronique Eparvier, Marc Litaudon, Philippe Grellier, Françoise Guéritte

▶ To cite this version:

Guillaume Marti, Véronique Eparvier, Marc Litaudon, Philippe Grellier, Francoise Guéritte. A New Xanthone from the Bark Extract of Rheedia acuminata and Antiplasmodial Activity of Its Major Compounds. Molecules, 2010, 15 (10), pp.7106-7114. 10.3390/molecules15107106. mnhn-02047400

HAL Id: mnhn-02047400 https://mnhn.hal.science/mnhn-02047400

Submitted on 24 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Article

A New Xanthone from the Bark Extract of *Rheedia acuminata* and Antiplasmodial Activity of Its Major Compounds

Guillaume Marti ¹, Véronique Eparvier ^{2,*}, Marc Litaudon ¹, Philippe Grellier ³ and Françoise Guéritte ¹

- ¹ Centre de Recherche de Gif, Institut de Chimie des Substances Naturelles, CNRS, 1 avenue de la Terrasse, 91198 Gif-sur-Yvette Cedex, France; E-Mails: guillaume.marti@icsn.cnrs-gif.fr (G.M.); marc.litaudon@icsn.cnrs-gif.fr (M.L.); francoise.gueritte@icsn.cnrs-gif.fr (F.G.)
- ² UPS2561, CNRS, 2, avenue Gustave Charlery, 97300 Cayenne, France
- Muséum National d'Histoire Naturelle, FRE 3206 CNRS, CP52, 61 rue Buffon, 75231 Paris cedex 05, France; E-Mail: grellier@mnhn.fr (P.G.)
- * Author to whom correspondence should be addressed; E-Mail: veronique.eparvier@guyane.cnrs.fr; Tel.: +594-594-29-75-16; Fax: +594-594-28-47-86.

Received: 21 August 2010; in revised form: 23 September 2010 / Accepted: 3 October 2010 / Published: 14 October 2010

Abstract: Bioassay-guided fractionation of the ethyl acetate bark extract of *Rheedia acuminata* led to the isolation of the new compound 1,5,6-trihydroxy-3-methoxy-7-geranyl-xanthone (1), together with four known compounds 2-5. These compounds were tested *in vitro* for their antiplasmodial activity on a chloroquine-resistant strain of *Plasmodium falciparum* (FcB1) and for their cytotoxicity against the human diploid embryonic lung cell line MRC-5.

Keywords: Rheedia acuminata, Clusiaceae; xanthones; antiplasmodial activity; cytotoxicity

1. Introduction

In South America several species of Clusiaceae are widely used in the manufacture of hulls, and well known for quality of their wood and for the healing properties of their latex used traditionally used for their effectiveness against dermatoses [1]. One of these, *Rheedia acuminata* (Ruiz & Pavon) Planchon and Triana, a tree growing in Amazonian rainforest, possesses an abundant latex used for

various medicinal purposes by the Guianese Amerindians (Palikur) in the form of patches or breakdowns applied to the wrinkling muscle. In addition, *Rheedia acuminata* fruits are commonly consumed in South America [1].

Prenylated xanthones and **p**oly**p**renylated **a**cyl**p**hloroglucinols (PPAPs) are widely distributed in the Clusiaceae, the genus *Rheedia* being a rich source of them [2-5]. Some biflavonoids were also previously isolated from this species [6]. Their biological activities include antibacterial, analgesic and cytotoxic properties [5,7,8].

In an effort to find new natural antimalarial drugs and as part of investigation of French Guiana plants, we found that the ethyl acetate extract of the bark of *Rheedia acuminata* showed antiplasmodial activity (92% of inhibitory growth of *Plasmodium falciparum* (FcB1) at 10 μ g/mL), whereas leaves and fruits extracts showed no significant and weak activity respectively (28% and 50% of inhibitory growth at 10 μ g/mL, respectively). We report here the bioassay-guided fractionation of this extract on the basis of this antiplasmodial activity.

2. Results and Discussion

The bioguided fractionation of the ethyl acetate extract of trunk bark of *Rheedia acuminata* led to the isolation of the new 1,5,6-trihydroxy-3-methoxy-7-geranyl-xanthone (1) along with two xanthone analogues (2 and 3) and two PPAPs (4 and 5) (Figure 1).

Figure 1. Structures of compounds 1-5.

Compound **1** was obtained as a yellow oil. The HREIMS indicated a [M+H]⁻ ion peak at m/z 409.1652, giving the molecular formula $C_{24}H_{25}O_6$ (calc. 409.1651). The IR spectrum displayed free hydroxyl (3,410 cm⁻¹), chelated hydroxyl (3,170 cm⁻¹), conjugated carbonyl (1,640 cm⁻¹) and aromatic ring (1,570 cm⁻¹) peaks. These data, together with absorption bands observed at λ_{max} 251, 283 and 327 nm in the UV spectrum and those obtained from 1D and 2D NMR experiments of compound **1**

suggested the presence of a 1,3,5,6-tetraoxygenated xanthone system [10,11]. Examination of the 1 H- NMR spectrum showed the presence of three hydroxyl groups with two broad signals at δ_{H} 7.88, 12.68 and one singlet at δ_H 14.02 ppm, corresponding to a chelated proton, one singlet at δ_H 8.08, two meta-coupled protons at δ_H 6.56 and 6.04 (1H, d, J = 2.3 Hz), and one methoxyl (δ_H 3.63). In addition two vinyl protons at δ_H 5.77 and 5.26 (1H, *brt*, J = 6.8 Hz), three methylene groups at δ_H 3.83 (2H, d, J = 7.3 Hz), 2.21 (2H, m) and 2.15 (2H, m), and three methyl groups at $\delta_{\rm H}$ 1.84, 1.69, 1.59 (3H, s) suggested the presence of a geranyl side chain. HSQC experiments allowed the assignment of all protonated carbons. A combination of HMBC, COSY and NOESY experiments were used to establish the position of the substituents. In the HMBC spectrum (Figure 2), the chelated proton OH-1 showed correlations with C-2 at δ_c 97.6 on one hand, and the proton H-2 with carbons C-9a (δ_C 104.2), C-4 $(\delta_C$ 92.8), C-1 $(\delta_C$ 164.7) and C-3 $(\delta_C$ 166.7) on the other hand. A methoxy group was deduced from the correlation between the methyl protons at δ_H 3.63 with C-3. NOESY correlations between the methoxy at C-3 with protons H-2 (δ_H 6.56) and H-4 (δ_H 6.04) confirmed the position of the substituents on ring A (Figure 2). Furthermore, HMBC correlations observed between H-8 and C-9 $(\delta_{\rm C} 181.5)$ were indicative of a *peri* location of the carbonyl. In addition, proton H-8 showed correlations with C-6 (δ_C 153.4), C-4b (δ_C 146.6), and CH₂-1' (δ_C 29.5) and a long-range correlation with C9a ($\delta_{\rm C}$ 104.2). The geranyl side chain was deduced from the COSY spectrum with, on one hand, correlations observed between Me-9' and Me-10' [δ_H 1.59 (3H, s, H-9') and 1.69 (3H, s, H-10')] and the vinylic proton H-7' at δ_H 5.28 (1H, brt, J = 6.8 Hz), which in turn showed a cross peak with H_2 -6'(δ_H 2.21, 2H, m). On the other hand, correlations observed between H_2 -5' (δ_H 2.16, 2H, m) and H₂-6' and H-2' at $\delta_{\rm H}$ 5.77 (1H, brt, J = 6.8 Hz), which in turn showed correlations with Me-4'($\delta_{\rm H}$ 1.84, 3H, s) and H₂-1'($\delta_{\rm H}$ 3.83, 2H, d, J=7.3 Hz) confirmed the presence of a geranyl side chain. The E configuration of the C-2'-C-3' double bond was established by NOESY correlations observed between H₂-5' with H-2', and Me-4'with H₂-1' (Figure 2). Finally, the position of the geranyl side chain at C-7 $(\delta_{\rm C} 127.8)$ was confirmed by HMBC correlation from H₂-1' to C-6 ($\delta_{\rm c} 153.4$) (Figure 2). Compound 1, which was named 1,5,6-trihydroxy-3-methoxy-7-geranylxanthone, is a positional isomer of cowaxanthone and rubraxanthone isolated from *Garcinia cowa* [12,13].

Figure 2. Key COSY (bold), HMBC (plain arrows) and NOESY (dashed arrows) correlations for **1**.

Compound 2 was identified as 2-(1'-1'-dimethylprop-2'-enyl)-1,4,5-trihydroxyxanthone and compound 3 as pyrojacareubin by comparison of the UV, HRESIMS, 1D and 2D NMR with the

literature data [13-15]. The 1D and 2D NMR spectra associated with their optical rotation values confirmed that **4** was isogarcinol [16-18] and **5**, 7-epi-isogarcinol [16].

The antiplasmodial activity against the chloroquine-resistant strain of P. falciparum FcB1 and the cytotoxicity upon the human diploid embryonic cell line MRC-5 of compounds **1-5** are summarized in Table 1. The three xanthones **1**, **2** and **3** isolated from *Rheedia acuminata* bark have IC₅₀s against *Plasmodium falciparum* exceeding 10 μ M. Compounds **4** and **5** have shown the best activity with IC₅₀s around 3 μ M. The IC₅₀ values obtained on MRC-5 cell line indicated that PPAPs **4** and **5** exhibited significant cytotoxicity whereas xanthones (**1** to **3**) showed weak cytotoxicity. Several xanthones, which have been isolated from various species of the family Clusiaceae, showed cytotoxic and antiplasmodial activities [9,10,19,20] and structure-activity relationships have been proposed in this series. For example, Winter *et al.* have demonstrated that xanthones with a hydroxyl group in *peri* positions with regards to the carbonyl (such as **1**, **2** and **3**), possess weak antiplasmodial activity due to their low affinity for the heme [21,22]. In conclusion, the antiplasmodial activity detected in the crude extract is probably due to the presence of high quantity of the two PPAPs **4** and **5**.

Table 1. IC₅₀ values of compounds **1-5** tested against FcB1 strain of *P. falciparum* and MRC-5 cell.

| Compound | IC ₅₀ <i>P.f.</i> FcB1 (μ M) \pm SD (n=3) | IC_{50} MRC-5 (μ M) ± SD (n=3) |
|-------------|---|---------------------------------------|
| 1 | 10.5 ^a | 36 ^a |
| 2 | 15.1 ^a | b |
| 3 | 11.4 ^a | 29 ^a |
| 4 | 3.5 ± 1.1 | 3.5 ± 0.4 |
| 5 | 3.2 ± 1.3 | 2.3 ± 0.5 |
| Chloroquine | 0.078 ± 0.006 | |
| Taxotere | | 31.5 ± 4.5 |

^a biological assays in duplicates; ^b not enough material.

3. Experimental

3.1. General

The NMR spectra were recorded on a Bruker 500 MHz (Avance 500) or 300 MHz (Aspect DPX 300 MHz) spectrometer. ESIMS were obtained on a Thermoquest Navigator mass spectrometer. HRESIMS were obtained on a ESI-TOF spectrometer (LCT; Waters). Kromasil analytical, semi-preparative and preparative C-18 columns (250 × 4.5 mm; 250 × 10 mm and 250 × 21.2 mm I.D, 5 μM Thermo[®]) were used for preparative HPLC separations using a "Waters autopurification system" equipped with a sample manager (Waters 2767), a column fluidics organizer, a binary pump (Waters 2525), a UV-Vis diode array detector (190-600nm), Waters 2996) and PL-ELS 1000 ELSD detector Polymer laboratory. IR spectra were obtained on a Nicolet FTIR 205 spectrophotometer. The UV spectra were recorded on a Perkin-Elmer Lambda 5 spectrophotometer. Specific rotation was obtained in CHCl₃ with a JASCO P-1010 polarimeter. Silica gel 60 (35–70 μm) and analytical TLC plates (Si gel 60 F 254) were purchased from SDS (France). Polyamide DC 6 and polyamide cartridge were purchased from Macherey-Nagel (Chromabond PA, 1 g).

3.2. Plant Material

Trunk bark of *R. acuminata* were collected in French Guiana. A voucher specimen (PMF-258) was deposited in the Herbarium of Cayenne (French Guiana), and identified by M-F. Prévost (IRD).

3.3. Extraction and Isolation

Trunk bark (370 g) were extracted three times with EtOAc (3 × 1L) at 40 °C and 1,450 psi on a Zippertex[®] static high-pressure high-temperature extractor developed in the ICSN Pilot Unit. This extract (10 g) was filtered on polyamide. Filtered extract (9.3 g) was subjected to silica gel chromatography using heptane/EtOAc mixtures (100/0-0/100). According to their TLC profile, 10 fractions were obtained (F1-F10). Fraction F4 (1.1 g), which showed antiplasmodial activity, was subjected to a preparative C-18 column using an isocratic mobile phase consisting of ACN/water + 0.1 % formic acid (flow rate 21 mL/min). This resulted in the isolation of 4 (72 mg, 0.019%), 5 (65 mg, 0.017%), 3 (2 mg, 0.0008%), 1 (8 mg, 0.0021%) and 2 (18 mg, 0.004%) with retention times of 15.5, 13.5, 10.4, 9.4, and 4.6 mins, respectively.

1,5,6-Trihydroxy-3-methoxy-7-geranylxanthone (1): Yellow oil; UV (MeOH) λ_{max} (log ε): 327 (3.99), 283 (3.96), 251 (4.35); IR ν_{max} (ns) 3410, 1640, 1570, 1450, 1370, 1290, 1220 cm⁻¹; ¹H-NMR (pyridine- d_5 , 500 MHz): δ 14.02 (1H, s, OH-1), 12.68 (1H, brs, OH), 8.08 (1H, s, H-8), 7.88 (1H, brs, OH) 6.56 (1H, d, J = 2.3 Hz, H-2), 6.04 (1H, d, J = 2.3 Hz, H-4), 5.77 (1H, brt, J = 6.8 Hz, H-2'), 5.28 (1H, brt, J = 6.8 Hz, H-7'), 3.83 (2H, brd, J = 7.3 Hz, H-1'), 3.63 (3H, s, OMe-3), 2.21 (2H, m, H-6'), 2.15 (2H, m, H-5'), 1.84 (3H, s, H-4'), 1.69 (3H, s, H-10'), 1.59 (3H, s, H-9'); ¹³C-NMR (pyridine- d_5 , 125 MHz): δ 181.5 (C-9), 166.7 (C-3), 164.7 (C-1), 158.5 (C-4a), 153.4 (C-6), 146.6 (C-4b), 137.2 (C-3'), 133.9 (C-5), 131.8 (C-8'), 127.8 (C-7), 125.3 (C-7'), 123.5 (C-2'), 116.7 (C-8), 113.8 (C-8a), 104.2 (C-9a), 97.6 (C-2), 92.8 (C-4), 56.2 (O-CH₃), 40.5 (C-5'), 29.5 (C-1'), 27.5 (C-6'), 26.2 (C-9'), 17.7 (C-4'), 18.2 (C-10'); HREIMS [M-H]⁻ m/z 409.1697, $C_{24}H_{26}O_6$ requires 409.1651.

2-(1',1'-Dimethylprop-2'-enyl)-1,4,5-Trihydroxyxanthone (2): Yellow powder; UV (MeOH) λ_{max} (log ε): 320 (3.61), 263 (4.12), 249 (4.12), 236 (4.07); IR ν_{max} (ns) 3570, 1720, 1680, 1540, 1270, 1120 cm ¹; ¹H-NMR (pyridine- d_5 , 500 MHz): δ 13.55 (1H, s, -OH), 7.99 (1H, dd, J = 8.0 Hz, H-8), 7.72 (1H, s, H-3), 7.53 (1H, dd, J = 8.3, 1.5 Hz, H-6), 7.27 (1H, t, J = 8.0 Hz, H-7), 6.47 (1H, dd, J = 17.1, 10.4 Hz, H-2'), 5.15 (2H, m, H-3'), 1.66 (6H, H-4', H-5'); ¹³C- NMR (pyridine- d_5 , 125 MHz): δ 184.4 (C-9), 153.2 (C-1), 149.7 (C-5), 148.7 (C-2'), 148.6 (C-4b), 144.2 (C-4a), 138.1 (C-4), 128.7 (C-2), 124.7 (C-3), 124.6 (C-7), 123.4 (C-8a), 122.2 (C-6), 116.1 (C-8), 112.3 (C-3'), 110.1 (C-9a), 41.1 (C-1'), 27.2 (C-4', C-5'); HREIMS [M-H] m/z 311,0934, $C_{18}H_{16}O_5$ requires 311.0919.

Pyrojacareubine (**3**): Orange-yellow powder; UV (MeOH) λ_{max} (log ε): 329 (3.42), 276 (4,18), 220 (4.08); IR ν_{max} (ns) 3330, 1650, 1580, 1490, 1450, 1290, 1220 cm⁻¹; ¹H-NMR (pyridine- d_5 , 500 MHz): δ 13.05 (1H, s, 1-OH), 7.46 (1H, s, H-8), 6.90 (1H, d, J = 10.0 Hz, H-2'), 6.45 (1H, d, d = 10.1 Hz, H-7'), 6.27 (1H, d), 5.74 (1H, d), d = 10.1 Hz, H-8'), 5.62 (1H, d), d = 10.0 Hz, H-3'), 1.55 (6H, d), H-10', H-11'), 1.50 (6H, d), H-6'); ¹³C-NMR (pyridine- d_5 , 125 MHz): δ 180.8 (C-9), 164.2 (C-1), 161.5 (C-3), 146.4 (C-4a), 131.0 (C-8'), 127.2 (C-3'), 121.4 (C-7'), 118.2 (C-7), 115.2 (C-2'), 113.5

(C-8), 110.4 (C-8a), 103.3 (C-2), 101.6 (C-9a), 99.4 (C-4), 78.9 (C-9'), 78.2 (C-4'), 28.4 (C-10', C-11'), 28.3 (C-5', C-6'); HREIMS [M-H] $^{-}$ m/z 391.1177, $C_{23}H_{19}O_6$ requires 391.1182.

Isogarcinol (4): Brown powder; $[α]^{25}_{D} = -160$ (c = 1.0, CHCl₃); UV (MeOH) $λ_{max}$ (log ε): 317 (3.82), 277 (4,14), 233 (4.07); IR v_{max} (ns) 3290, 2920, 2850, 1730, 1670, 1590, 1520, 1440, 1370, 1290, 1170 cm⁻¹; ¹H- NMR (pyridine- d_5 , 500 MHz): δ 8.05 (1H, d, J = 2.0 Hz, H-12), 7.68 (1H, dd, J = 8.1, 2.0 Hz, H-16), 7.28 (1H, d, J = 8.1 Hz, H-15), 5.42 (1H, tl, J = 6.5 Hz, H-18), 5.09 (2H, tl, J = 6.5 Hz, H-35, H-25), 3.27 (1H, dd, J = 13.9, 3.1 Hz, H-29), 3.21 (1H, ddd, J = 14.4, 10.7, 9.5 Hz, H-24), 2.76 (1H, dd, J = 13.7, 5.6 Hz, H-17), 2.43 (1H, dl, J = 14.1 Hz, H-8), 2.42 (1H, dl, J = 14.1 Hz, H-24),2.11 (1H, dd, J = 14.1, 7.3 Hz, H-8), 1.96 (1H, dl, J = 14.1 Hz, H-34), 1.91 (3H, s, H-28), 1.82 (1H, ddd, J = 14.2, 9.5, 9.5 Hz, H-34), 1.74 (3H, s, H-27), 1.71 (3H, s, H-21), 1.68 (3H, s, H-37), 1.66 (1H, dt, J = 9.9, 5.0 Hz, H-30), 1.57 (3H, s, H-20), 1.56 (3H, s, H-38), 1.54 (1H, m, H-7), 1.30 (3H, s, H-23), 1.23 (3H, s, H-32), 1.14 (1H, dd, J = 13.9, 13.7 Hz, H-29), 1.07 (3H, s, H-33), 1.05 (3H, s, H-22); ¹³C-NMR (pyridine-d₅, 125 MHz): δ 207.9 (C-9), 195.0 (C-4), 193.0 (C-10), 172.2 (C-3), 171.4 (C-2), 153.7 (C-14), 147.8 (C-13), 134.5 (C-19), 133.7 (C-36), 132.9 (C-26), 130.9 (C-11), 126.4 (C-25), 124.3 (C-16), 122.8 (C-35), 121.7 (C-18), 116.6 (C-12), 116.5 (C-15), 87.2 (C-31), 69.2 (C-5), 52.2 (C-1), 47.0 (C-7), 46.8 (C-6), 43.8 (C-30), 39.8 (C-8), 30.4 (C-34, C-24), 29.4 (C-33), 29.1 (C-29), 27.1 (C-22), 26.7 (C-17), 26.6 (C-20), 26.5 (C-27), 26.2 (C-37), 23.1 (C-23), 21.7 (C-32), 19.0 (C-28), 18.8 (C-21), 18.3 (C-38); HREIMS $[M-Na]^+$ m/z 625.3499, $C_{38}H_{50}O_6$ requires 625.3505.

7-epi-Isogarcinol (5): Brown powder; $[\alpha]^{25}_D = -158$ (c = 1.0, CHCl₃); UV (MeOH) λ_{max} (log ϵ): 319 (3.85), 276 (4.15), 233 (4.12); IR v_{max} (ns) 3320, 2970, 2930, 1730, 1650, 1590, 1520, 1440, 1370, 1290, 1170 cm⁻¹; ¹H- NMR (pyridine- d_5 , 500 MHz): δ 8.13 (1H, sl, H-12), 7.72 (1H, dl, J = 7.7 Hz, H-16), 7.31 (1H, dl, J = 7.6 Hz, H-15), 5.38 (1H, tl, J = 6.2 Hz, H-18), 5.18 (1H, tl, J = 6.2 Hz, H-25), 5.13 (1H, tl, J = 6.6 Hz, H-35), 3.28 (1H, dd, J = 13.9, 3.2 Hz, H-29), 2.97 (1H, dd, J = 13.6, 6.4 Hz, H-17), 2.77 (1H, dd, J = 13.6, 4.8 Hz, H-17), 2.44 (1H, m, H-7), 2.43 (1H, m, H-8), 2.26 (1H, dd, J = 14.1, 2.5 Hz, H-24, 1.96 (1H, m, H-34), 1.82 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J = 14.1, 8.5 Hz, H-24), 1.79 (1H, dd, J =1.77 (1H, m, H-8), 1.73 (3H, s, H-21), 1.71 (3H, s, H-37), 1.65 (1H, m, H-30), 1.62 (6H, s, H-27, H-28), 1.56 (3H, s, H-38)1.55 (3H, s, H-20), 1.27 (3H, s, H-23), 1.21 (1H, dd, J = 13.9, 13.7 Hz, H-29), 1.14 (3H, s, H-32), 1.08 (3H, s, H-33), 0.83 (3H, s, H-22); 13 C-NMR (pyridine- d_5 , 125 MHz): δ 207.3 (C-9), 194.9 (C-4), 193.2 (C-10), 170.8 (C-2), 153.7 (C-14), 147.9 (C-13), 134.2 (C-19), 133.7 (C-36), 132.9 (C-26), 131.0 (C-11), 129.1 (C-3), 124.4 (C-16), 123.8 (C-25), 122.9 (C-35), 122.1 (C-18), 117.1 (C-12), 116.5 (C-15), 87.6 (C-31), 71.4 (C-5), 52.2 (C-1), 46.8 (C-6), 43.8 (C-30), 43.1 (C-8), 42.2 (C-7), 30.4 (C-34), 29.2 (C-33), 28.5 (C-24, C-29), 26.2 (C-27), 25.9 (C-17), 26.2 (C-37, C-20), 22.8 (C-23), 21.7 (C-32), 18.8 (C-21), 18.4 (C-28), 18.3 (C-38), 16.6 (C-22); HREIMS [M-Na]⁺ m/z 625.3519, $C_{38}H_{50}O_6$ requires 625.3505.

3.4. Biological Activities

The extracts and compounds were tested against the chloroquine-resistant FcB1/ Colombia strain of *Plasmodium falciparum* in 96-well plates by measuring [3H]-hypoxanthine incorporation by parasite as previously described [23]. The growth inhibition for each compound concentration was determined by comparing the radioactivity incorporated in the treated culture with that in the control culture

maintained on the same plate. The concentrations causing 50% inhibition of parasite growth (IC50) were calculated from the drug concentration-response curves. Chloroquine[®] was used as a control compound.

The human diploid embryonic lung cells MRC-5 were seeded into 96-well microplates at 2000 cells per well. The cytotoxicity assays were performed according to a published procedure [24]. Taxotere® was used as a control compound.

4. Conclusions

A chemical investigation of *Rheedia acuminata* bark was carried out in the framework of a global investigation on French Guiana flora. This study showed that the bark contained a new xanthone, 1,5,6-trihydroxy-3-methoxy-7-geranylxanthone, together with 2-(1'-1'-dimethylprop-2'-enyl)-1,4,5-trihydroxyxanthone. Pyrojacareubin, isogarcinol and 7-*epi*-isogarcinol were isolated from the *Rheedia* genus, for the first time. The two PPAPs isolated from *Rheedia acuminata*, which exhibited cytotoxic and antiplasmodial properties, were likely responsible of the biological activity found in the crude extract.

Acknowledgements

This work was supported by an ICSN-CNRS grant. We are grateful to Marie-Françoise Prévost (IRD) for her help in the identification of plant collection, Marie-Thérese Martin for her assistance in the structural determination and Geneviève Aubert (ICSN) who performed the cytotoxic assays on MRC-5 cells. All work carried out and reported in this manuscript is based on the program "Valorization of French Guiana flora" (CNRS, IRD, UMR Ecofog) with the financial support of the "Institut de Chimie des Substances Naturelles" (CNRS, France).

References

- 1. Grenand, P.; Moretti, C.; Jacquemin, H.; Prévost, M-F. *Pharmacopées Traditionnelles en Guyane. Créoles*, *Palikur*, *Wayãpi*; 2nd ed.; IRD: Marseille, France, 2004; pp. 309-319.
- 2. Peres, V.; Nagem, T.J.; Oliveira, F.F. Tetraoxygenated naturally occurring xanthones. *Phytochemistry* **2000**, *55*, 683-710.
- 3. Peres, V.; Nagem, T.J. Trioxygenated naturally occurring xanthones. *Phytochemistry* **1997**, *44*, 191-214.
- 4. Torrico, F.; Velasco, P.; Gimenez, A.; Almanza, G.R. An antibacterial xanthone and triterpenes of *Rheedia acuminata. Rev. Boliv. Quim.* **2001**, *18*, 38-42.
- Cao, S.; Brodies, P.J.; Miller, J.S.; Ratovoson, F.; Birkinshaw, C.; Randrianasolo, S.; Rakotobe, E.; Rasamison, V.E.; Kingston, D.G.I. Guttiferones K and L, Antiproliferative compounds of *Rheedia calicola* from the Madagascar rain forest. *J. Nat. Prod.* 2007, 70, 686-688.
- 6. Li, X-C.; Joshi, A.S.; Tan, B.; ElSohly, H.N.; Walker, L.A.; Zjawiony, J.K.; Ferreira, D. Absolute configuration, conformation, and chiral properties of flavanone-(3→8")-flavone biflavonoids from *Rheedia acuminata*. *Tetrahedron* **2002**, *58*, 8709-8717.

7. Almeida, L.S.B.; Murata, R.M.; Yatsuda, R.; Dos Santos, M.H.; Nagem, T.J.; Alencar, S.M.; Koo, H.; Rosalen, P.L. Antimicrobial activity of *Rheedia brasiliensis* and 7-epiclusianone against *Streptococcus mutans*. *Phytomedicine* **2008**, *15*, 886-891.

- 8. Verdi, L.G.; Pizzolatti, M.G.; Montanher, A.B.P.; Brighente, I.M.; Smânia Júnior, A.; Smânia, E.D.F.A.; Simionatto, E.L.; Delle Monache, F. Antibacterial and brine shrimp lethality tests of biflavonoids and derivatives of *Rheedia gardneriana*. *Fitoterapia* **2004**, *75*, 360-363.
- 9. Zelefack ,F.; Guilet, D.; Fabre, N.; Bayet, C.; Chevalley, S.; Ngouela, S.; Ndjakou Lenta, B.; Valentin, A.; Tsamo, E.; Dijoux-Franca, M-J. Cytotoxic and antiplasmodial xanthones from *Pentadesma butyracea*. *J. Nat. Prod.* **2009**, *72*, 954-957.
- 10. Han, A.R.; Kim, J.A.; Lantvit, D.D.; Kardono, L.B.S.; Riswan, S.; Chai, H.; De Blanco, E.J.C.; Farnsworth, N.R.; Swanson, S.M.; Kinghorn, A.D. Cytotoxic xanthone constituents of the stem bark of *Garcinia mangostana* (mangosteen). *J. Nat. Prod.* **2009**, *72*, 2029-2031.
- 11. Pattalung, P.; Thongtheeraparp, W.; Wiriyachitra, P.; Taylor, W.C. Xanthones of *Garcinia cowa*. *Planta Medica* **1994**, *60*, 365-368.
- 12. Lee, H-H.; Chan, H-K. 1,3,6-Trihydroxy-7-methoxy-8-(3,7-dimethyl-2,6-octadienyl)xanthone from *Garcinia cowa*. *Phytochemistry* **1977**, *16*, 2038-2040.
- 13. Sordat-Diserens, I.; Marston, A.; Hamburger, M.; Hostettman, K. Novel prenylated xanthones from *Garcinia gerrardii* Harvey. *Helv. Chim. Acta* **1989**, *72*, 1001-1007.
- 14. Monach, G.D.; Monache, F.D.; Waterman, P.G.; Crichton, E.G.; De Limas, R.A. Minor xanthones from *Rheedia gardenaria*. *Phytochemistry* **1984**, *23*, 1757-1759.
- 15. Harrison, L.J.; Leong, L.S.; Sia, G.L.; Sim, K.Y.; Tan, H.T.W. Xanthones from *Garcinia forbesii*. *Phytochemistry* **1993**, *33*, 727-728.
- 16. Marti, G.; Eparvier, V.; Moretti, C.; Susplugas, S.; Prado, S.; Grellier, P.; Retailleau, P., Guéritte, F.; Litaudon M. Antiplasmodial benzophenones from the trunk latex of *Moronobea coccinea* (Clusiaceae). *Phytochemistry* **2009**, *70*, 75-85.
- 17. Ciochina, R.; Grossman, R.B. Polycyclic polyprenylated acylphloroglucinols. *Chem. Rev.* **2006**, *106*, 3963-3986.
- 18. Hamed, W.; Brajeul, S.; Mahuteau-Betzer, F.; Toison, O.; Mons, S.; Delpech, B.; Hung, N.V.; Sevenet, T.; Marazano, C. Polyprenylated benzoylphloroglucinol derivatives from *Garcinia oblongifolia*. J. Nat. Prod. **2006**, 69, 774-777.
- 19. Azebaze, A.G.B.; Meyer, M.; Valentin, A.; Nguemfo, E.L.; Fomum, Z.T.; Nkengfack, A.E. Prenylated xanthone derivatives with antiplasmodial activity from *Allanblackia monticola* Staner L.C. *Chem. Pharm. Bull.* **2006**, *54*, 111-113.
- 20. Tao, S.J; Guan, S.H.; Wang, W.; Lu, Z.Q.; Chen, G.T.; Sha, N.; Yue, Q.X.; Liu, X.; Guo, D.A. Cytotoxic polyprenylated xanthones from the resin of *Garcinia hanburyi*. *J. Nat. Prod.* **2009**, *72*, 117-124.
- 21. Ignatushchenko, M.V.; Winter, R.W.; Riscoe, M. Xanthones as antimalarial agents: Stage specificity. *Am. J. Trop. Med. Hyg.* **2000**, *62*, 77-81.
- 22. Ignatushchenko, M.V.; Winter, R.W.; Bächinger, H.P.; Hinrichs, D.J. Riscoe, M.K. Xanthones as antimalarial agents; studies of a possible mode of action. *FEBS Letters* **1997**, 409, 67-73.

23. Frappier, F.; Jossang, A.; Soudon, J.; Calvo, F.; Rasoinevo, P.; Ratsimamanga-Urverg, S.; Saez, J.; Schrevel, J.; Grellier, P. Bisbenzylisoquinolines as modulators of chloroquine resistance in *Plasmodium falciparum* and multidrug resistance in tumor cells. *Antimicrob. Agents Chemother.* **1996**, *40*, 1476-1481.

24. Tempete, C.; Werner, G.H.; Favre, F.; Rojas, A.; Langlois, N. *In vitro* cytostatic activity of 9-demethoxyporothramycin B. *Eur. J. Med. Chem.* **1995**, *30*, 647-650.

Sample Availability: Samples of the compounds are available from the authors.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).